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our clinical results and introduce the current status of stereotactic body 
radiotherapy (SBRT) for lung cancer.
Materials and Methods: More than 200 patients have been treated 
with SBRT. Forty-ﬁve patients who were treated between September 
1998 and July 2003 were evaluated. Thirty-one patients had Stage IA 
lung cancer, and the other 14 had Stage IB lung cancer whose tumor 
size was less than 4 cm in diameter. Three-dimensional treatment plan-
ning using 6 to 10 non-coplanar beams was performed to maintain the 
target dose homogeneity, and to decrease the irradiated lung volume 
>20 Gy. All patients were irradiated using a stereotactic body frame and 
received 4 times 12 Gy single high dose radiation at the isocenter over 
a period of 5-13 (median=12) days.
Results: Seven tumors (16%) disappeared completely after treatment 
(CR). Thirty-eight tumors (84%) decreased in size by 30% or more 
(PR) after treatment. Therefore, all tumors showed local response. 
During the follow-up of 5-63 (median=23) months, no pulmonary 
complications greater than an NCI-CTC criteria of grade 3 were noted. 
No other serious complications have not been encountered. All tumors 
except one were locally controlled without apparent evidence of local 
failure during the follow-up period. However, regional nodal recurrenc-
es and distant metastases were in three and four of T1 patients, zero and 
four of T2 patients respectively.
Discussion: The key issues for SBRT are ﬁxing apparatus, respira-
tory regulation, treatment planning and veriﬁcation. A few types of 
stereotactic body frames are available. For regulation of respiratory 
movement, abdominal wall compression, breath-holding, respiratory 
gating and tumor chasing methods were used. For irradiation technique, 
6 to 10 non-coplanar beams or multiple arc beams were adopted. Daily 
veriﬁcation is mandatory for SBRT. Portal ﬁlms, EPID and CT on rails 
were used. Frequently used radiation regimens were 48 to 60 Gy in 3 
to 5 fractions. Single dose radiosurgery technique is still pursued in a 
few institutes. The local control rates were almost always above 90 % 
for lung cancer, with few complications. Long term follow-up results 
have also been reported. Several unanswered questions and currently 
ongoing protocols will be also reviewed. The patient accrual for RTOG 
0236, 60 Gy in 3 fractions was complete, and the operable patient ac-
crual for JCOG 0403, 48 Gy in 4 fractions were also ﬁnished. The other 
multi-institutional studies are underway. 
Conclusions: SBRT seems to be a promising method especially for the 
treatment of early stage lung cancer. 
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Improper knowledge of the patient’s anatomy and position during the 
course of therapy has always been a major source of concern in radia-
tion therapy potentially compromising the clinical results by insuf-
ﬁcient dose coverage of the target volume and/or overdose of normal 
tissues. The management of target localization emanates in the concept 
of treatment margins to cope with the uncertainty of the true location 
of the target volume during irradiation (gross target volume or GTV; 
clinical target volume or CTV; set-up margin or SM; internal margin or 
IM; planning target volume or PTV; and planning risk volume or PRV). 
Concerning these so-called set-up uncertainties, it is generally accepted 
that 2 classes can be identiﬁed, systematic and random. Systematic 
errors exist because the imaging performed for treatment planning is 
typically a snapshot and the target position determined at that instant 
of time may differ from the average target position at treatment time, 
or if a certain procedure introduces an error that is repeated systemati-
cally in time. The random error is the day-to-day deviation from the 
average target position introduced with internal organ motion and the 
repeated treatment set-up that occurs in fractionated radiation therapy. 
The systematic error is generally considered more important, because 
if uncorrected it would propagate throughout the treatment course and 
lead to deleterious effect on local control. On the other hand day-to-
day variations may be substantial requiring safety margins that limit 
the maximum dose administered to the tumour volume due to possible 
toxicity to surrounding healthy tissue. With the introduction of image-
guided radiation therapy (IGRT) clinical conﬁdence has grown and the 
opportunity is given to examine whether the traditional fractionated 
radiation therapy at 2 Gy per fraction is still the optimum strategy. This, 
in turn, introduces treatment schedules using less fractions (so-called 
hypo-fractionation), and the day-to-day variation in target localization 
may no longer be statistically random. And ﬁnally, motion management 
becomes an issue as tumour motion interacts with dose delivery caus-
ing a dose spread along the path of motion in some delivery techniques.
With the improved imaging modalities to deﬁne and delineate tumour 
volumes, identifying both morphologic as well as functional and 
biologic information, and the introduction of treatment modalities that 
allow for shaped dose distributions (e.g. intensity modulated radiation 
therapy or IMRT, stereotactic body radiotherapy or SBRT, and charged 
particle beams), the radiotherapy community is now capable to create 
dose distributions that match the tumour volume tightly. Conformal 
radiation therapy (CRT) aims at shaping the dose distribution to the de-
lineated target volume, whereas conformal avoidance aims at avoiding 
critical structures. These advancements have been driven by the dual 
goals of maximizing radiation dose to tumour volume whilst minimiz-
ing dose to surrounding healthy tissue. It goes without saying that ac-
curate knowledge of the patient’s anatomy during the radiation process 
is of utmost importance and in fact it can be argued that these novel 
technologies such as IMRT and shaped beam radiosurgery are useless 
without proper image-guidance.
The concept of image-guidance as such is not new in radiotherapy. 
Aspects of image guidance have always existed, even with the ﬁrst 
use of x-rays for cancer therapy, probably using the same radiation 
source for both imaging and treatment. The concept of IGRT however, 
has been introduced as to deﬁne the accomplishment of tumour and 
soft tissue imaging in real-time or near real-time for correction of both 
systematic and random errors on a daily basis. It was born out of the 
need for accurate target localization required for IMRT and SBRT, 
and allowing delivery of boost doses to sub-volumes identiﬁed with 
functional and biological imaging. IGRT will be mandatory to exploit 
the possible clinical beneﬁts of these new treatment procedures. As the 
capabilities of IGRT improve, it will provide the tools to better under-
stand treatment uncertainties and allow a re-examination of the present 
practice regarding treatment margins. Conceptually, IGRT refers to 
in-room image-guidance just before or during treatment and is based 
on the assumption that the tumour volume has been deﬁned adequately. 
The imaging modalities applied for tumour identiﬁcation and delinea-
tion, although they also help to ìguide the treatmentî, are not part of the 
IGRT concept in its current deﬁnition.
For simplicity, an ideal IGRT system should have 3 essential elements: 
(a) 3D and if possible motion (4D) assessment of the target volume 
(preferably 3D volumetric information of soft tissue including tumour 
volume), (b) efﬁcient comparison of the image data with reference data, 
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and (c) an efﬁcacious and fast process for clinical meaningful interven-
tion (preferably fully automated). The clinical introduction of on-line 
electronic imaging devices (EPID) has led to the improved understand-
ing of treatment uncertainties, and of the need for strategies to further 
reducing them. Already in the early 90ís strategies had been developed 
to use EPID for near real-time patient set-up, and although the ﬁrst 
requirement (3D assessment) could be established by using multiple 
planar images, this procedure never became a mainstream solution as 
it was cumbersome for implementation into the daily workﬂow. Yet, 
this development did raise the awareness of the potential beneﬁts of 
image guidance and the concept IGRT was born. IGRT solutions could 
be classiﬁed as follows: (1) megavolt (MV) imaging, (2) kilovolt (kV) 
imaging, and (3) solutions using non-ionising radiation. Some of these 
IGRT techniques are designed for interfraction target localization, some 
techniques will be able to perform intrafraction target motion manage-
ment. In other words not limited to target observation only, but also 
offering the possibility of controlling the treatment beam based on that 
information for breathing synchronized irradiation. In principle 2 ap-
proaches exist: one uses the image guidance to align the target volume 
with respect to the treatment beam using a robotic couch control system 
in combination with a beam triggering system switching the beam 
on-and-off in synchronization with a breathing signal, the other in 
turn, uses the imaging information to guide the treatment beam using 
a robotic linac or computer control of the beam collimating system to 
actually follow the target during beam-on. The latter has the potential 
of true real-time tumor tracking, whereas the former can be used to gate 
the treatment in case of organ motion.
It will be shown, that the introduction of new technologies such as 
IGRT and 4D Radiation therapy signiﬁcantly helped reducing compli-
cations and paved the way for more aggressive treatment schedules, 
(in)directly improving outcome. It is with the clinical introduction 
of IGRT that we start to understand the true concept of margins and 
organ motion. The adoption of new technologies in IGRT, not only 
allowed for more precise and aggressive therapies, but also inﬂuenced 
the indications of radiation therapy and initiated a revision of gener-
ally accepted fractionation schemes and concepts of radiobiology. New 
imaging modalities help avoiding inter-observer variation, and provide 
increased functional/biological information of the tumour to focus the 
treatment more efﬁciently. These developments will guide us to “paint 
dose by numbers” acknowledging the heterogeneous nature of tumours 
so far neglected by delivering homogeneous dose distributions. Finally, 
this review will demonstrate the necessity of a close collaboration and 
synergy between the different disciplines in combating cancer.
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Background: Particle beams have a distinct physical advantage over 
conventional photon beams. Particle beams have a low entrance dose, a 
maximal dose at any prescribed depth, called the “Bragg peak”, and no 
exit dose. The “Bragg peak” can be spread out and shaped to conform 
to the depth and volume of an irregular target. Particle beam therapy 
(PBT) can thus create an inherently three-dimensional conformal dose 
distribution without extra dose to the surrounding normal tissue com-
pared with conformal photon treatment. At present, two particle beams 
are used for clinical purpose in the world. One is proton beam and 
the other is carbon-ion beam. The difference of these particle beams 
is its biological effect. Proton beam has a value of relative biological 
effectiveness (RBE) as 1.1, which would be considered to be almost 
identical biological effect with X-rays. In contrast, RBE of carbon-ion 
beam is estimated to be 3.0, and this high value is expected carbon-ion 
beam would be more effective for radio-resistant tumors. In Japan, PBT 
for lung cancer was performed under respiratory gating irradiation that 
means beam will turn on in only end expiration phase, and irradiated 
volume can be minimized. However, in western countries, respiratory 
gating system is rarely used.
Literature review: Most of the published articles employing PBT 
were focus on treating early stage no-small cell lung cancer (NSCLC), 
especially for Stage I disease. At University of Tsukuba, 51 NSCLC 
patients were treated with PBT with protons. Stage I, II, III, IV patients 
were 28, 9, 8, 5, respectively. The 5-year overall survival rate for Stage 
IA and IB were 70% and 16%, respectively (1). At Loma Linda Univer-
sity Medical Center, hypofractionated PBT with protons with 51 cobalt 
Gray equivalent (CGE) or 60 CGE in 10 fractions were delivered for 
22 and 46 Stage I NSCLC patients, respectively. With a median fol-
low-up period of 30 months, 3-year disease speciﬁc survival rates were 
72% (2). At the National Institute of Radiological Sciences in Japan, 
hypofractionated PBT with carbon-ions has been conducted (3-5). Re-
cently, results of 51 patients with Stage I NSCLC treated with 72 CGE 
in 9 fractions were reported. With a median follow-up period of 59.2 
months, 5-year cause speciﬁc survival rates were 75.7% (IA: 89.4; IB: 
55.1), and overall survival 50.0% (IA: 55.2%; IB: 42.9%). No severe 
acute and late toxicities were observed in all the published literatures.
NCC experiences: We already reported our initial experience of PBT 
with protons for Stage I NSCLC (6), and updated results were ana-
lyzed. Between December 1999 and September 2006, 77 patients with 
stage I NSCLC were treated by PBT with protons in our institution. 
The indication of PBT were 1) clinical stage I NSCLC, 2) PaO2 > 60 
torr, 3) medically inoperable, or refusal of surgery, 4) performance sta-
tus 0-2, 5) written informed consent. The target volume was deﬁned as 
the gross tumor volume (GTV) plus appropriate margins for subclinical 
tumor extension. In general, 8 mm margin was added for all directions 
as the clinical target volume (CTV). Margins for set-up error and respi-
ratory motion were added for planning target volume (PTV). Treatment 
was performed using respiratory gating with strain gauge. Based on 
the analysis of respiratory movement during gating irradiation, 5 mm 
internal margin for respiratory movement was added. A total dose of 
70 - 94 CGE was delivered in 20 fractions over 4 to 5 weeks. Kaplan-
Meier method and CTC-AE version 3.0 were used to assess survival 
and toxicity. 
Patients characteristics were as follows: median age 75 years (range, 52 
to 87); male/female, 54/23; Stage IA/IB, 43/34; squamous/ adeno-
carcinoma/ others, 28/23/26; total dose 70/80/88/94 CGE, 3/57/16/1. 
The initial response rate was 74% (95% conﬁdence interval (CI), 63 
to 83%). With a median follow-up period of 24 months (range, 3 to 82 
months), the 2-year local progression-free and overall survivals were 
94% (95%CI, 87 to 99%) and 91% (95% CI, 83 to 99%)(Fig.1), respec-
tively. No severe acute toxicity was observed. Late grade 2 and grade 
3 pulmonary toxicities were observed in 5 and 3 patients, respectively. 
Four patients experienced fractures of ribs within irradiated volume. 
The 2-year loco-regional progression-free survivals in stage IA and 
IB patients were 95% (95% CI, 88 to 100%) and 67% (95% CI, 50 to 
84%)(Fig. 2), respectively. Six of 8 patients who suffered late grade 2 
or greater pulmonary toxicities had stage IB disease. 
Conclusions: Literature review and updated our data show that PBT 
with both protons and carbon-ions is a promising treatment modal-
